Close menu




May 22nd, 2020 | 09:45 CEST

Burcon, HelloFresh, Memphasys, TUI - winners of the Corona crisis

  • Investments
Photo credits: pixabay.com

The past three months have changed the world. Since the outbreak of the Corona Pandemic, the travel business has come to a standstill and the supply of various food products and everyday items has been characterized by bottlenecks. The meat industry is struggling with infections among its employees as a result of the relentless price war. The easing of measures continues to increase and the pie is being redistributed in many parts of the economy. Opportunities for investors.

time to read: 2 minutes | Author: Mario Hose
ISIN: AU000000MEM5 , DE000TUAG000 , DE000A161408 , CA1208311029

Table of contents:


    Support in case of desire to have children

    Memphasys from Australia is active in the medical field and helps couples who wish to have children with artificial insemination. The company has developed a device called FELIX, with which high-quality sperm can be obtained from the man's seminal fluid through biological separation to increase the chances of success of a pregnancy afterwards. Memphasys serves a growing market with this solution, because more and more often couples wait until it is almost too late to have a child by natural means or until accompanying support is needed.

    In connection with the Corona Pandemic, this trend may be supported because the economic insecurity of the general public is increasing and the pressure to earn money is growing. The market value of Memphasys is approximately AUD 50 million and in the second half of 2020 FELIX will be launched in various markets around the world.

    Meat replacement on the rise

    In recent weeks there have been increasing reports about working conditions in slaughterhouses. Due to price pressure, employees from low-wage countries are often employed and housed in mass accommodation. The consequences are a high rate of infection among the employees, because quarantine of infected employees cannot be ensured and it is usually too late by the time an infection is noticed. Burcon NutraScience will be able to serve a market with its plant proteins that will have a competitive advantage through the replacement of ingredients derived from animals.

    Whether it's convenience foods or cappuccinos, Burcon's patented proteins will enable the company to scalably serve the meat replacement trend of the future. The company is currently working on building production capacity. Burcon's market capitalization is presently around CAD 140 million.

    Winners of Isolation and Social Phobia

    HelloFresh was definitely able to benefit from the changes and measures in daily shopping in the past months and the share price increased significantly. How sustainable the sale of ingredients and recipes in boxes will be will be shown by the publication of the financial statements in the coming quarters. As purchasing power declines, customers may be forced to economize and in connection with the flattening of the risk of infection by Covid-19, people will also go shopping in supermarkets again. It remains to be seen whether HelloFresh will hold a market value of EUR 6.4 billion.

    Start of the race to catch up

    The stock market value of the TUI travel group suffered considerably in the wake of the Corona Pandemic. With a market capitalisation of less than two billion euros, the value of the company is only slightly above the government support of EUR 1.8 billion. As an industry giant and a responsible brand, TUI is the first and the strongest beneficiary of the easing in the travel business and the increase in demand for travel. The curfews of recent months certainly do not alleviate wanderlust and the desire to travel. TUI's shares are likely to rise again in the coming days, weeks and months in the favour of investors and on the trading floor.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read